OncoGenex Pharmaceuticals, Inc. Logo

Email this page: News Release

OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by OncoGenex Pharmaceuticals, Inc. for any marketing purposes.

Send:       


 
This helps OncoGenex Pharmaceuticals, Inc. prevent automated submissions.